Host: John J. Russell, MD

Guest: Serge A. Jabbour, MD, FACP, FACE

Host Dr. John Russell welcomes Dr. Serge Jabbour, Professor and Endocrinology Division Director at Jefferson University Hospitals in Philadelphia, Pennsylvania. Dr. Jabbour is also the Director of the hospital’s Diabetes Center and Comprehensive Weight Management Program. Dr. Jabbour will review Farxiga® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dr. Jabbour will also discuss the efficacy and safety profile of FARXIGA and the clinical development studies. Brought to you by Indication and Limitation of Use For Farxiga® (dapagliflozin) FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Important Safety Information For Farxiga® (dapagliflozin) Contraindications History of a serious hypersensitivity reaction to FARXIGA Severe renal impairment, end stage renal disease, or patients on dialysis Warnings and Precautions Hypotension: FARXIGA causes intravascular volume contraction. Symptomatic hypotension can occur after initiating FARXIGA, particularly in patients with impaired renal function (eGFR <60 mL/min/1.73 m2), elderly patients, or patients on loop diuretics. Before initiating FARXIGA in patients ...